SCHEMBL17667166

SCHEMBL17667166

O=C(O)C1OC1C(=O)N(Cc1ccccc1)c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.55
▸ NPC1 O15118 2/20 0.51
▸ GLA P06280 1/20 0.51
▸ HTT P42858 1/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ PAX8 Q06710 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ TRPM8 Q7Z2W7 1/20 0.50
▸ S1PR1 P21453 1/20 0.44
▸ S1PR3 Q99500 1/20 0.44
▸ GAA P10253 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ PDK1 Q15118 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ PKM P14618 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17667165 1.00 ALDH1A1 (0.55) ALDH1A1NPC1GLAHTTRAB9A
SCHEMBL17667174 0.82 TSHR (0.51) ALDH1A1NPC1GLAHTTRAB9A
SCHEMBL17667175 0.82 TSHR (0.51) ALDH1A1NPC1GLAHTTRAB9A
SCHEMBL6069937 0.82 MEN1 (0.50) ALDH1A1SMN1; SMN2TSHRMEN1KMT2A
SCHEMBL6069582 0.79 NPC1 (0.53) ALDH1A1NPC1RAB9ASMN1; SMN2GAA
SCHEMBL17676840 0.79 ALDH1A1 (0.44) ALDH1A1NPC1GLAHTTRAB9A
SCHEMBL17676835 0.79 ALDH1A1 (0.44) ALDH1A1NPC1GLAHTTRAB9A
SCHEMBL17676841 0.78 ALDH1A1 (0.44) ALDH1A1NPC1GLAHTTRAB9A
SCHEMBL16276151 0.78 ALDH1A1 (0.44) ALDH1A1NPC1GLAHTTRAB9A
SCHEMBL19597244 0.78 ALDH1A1 (0.44) ALDH1A1NPC1GLAHTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3006432-B1 2,3-BUTANEDIAMIDE EPOXIDE COMPOUND AND PREPARATION METHOD AND USE THEREOF INST PHARMACOLOGY & TOXICOLOGY ACAD MILITARY MEDICAL SCIENCES PLA CHINA (CN) 2017-11-15 — — EP disclosed
CN-104211666-B 2,3 epoxy succinyl aminated compounds, preparation method and use 中国人民解放军军事医学科学院毒物药物研究所 2017-11-14 — — CN disclosed
US-9630957-B2 2,3-butanediamide epoxide compound and preparation method and use thereof INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) 2017-04-25 — — US disclosed
US-20160115160-A1 2, 3-Butanediamide Epoxide Compound and Preparation Method and Use Thereof INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) 2016-04-28 — — US disclosed
EP-3006432-A1 2,3-BUTANEDIAMIDE EPOXIDE COMPOUND AND PREPARATION METHOD AND USE THEREOF Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China (CN) 2016-04-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160115160-A1 2, 3-Butanediamide Epoxide Compound and Preparation Method and Use Thereof ECE2, GNE, EPHX2 ALDH1A1 446/4885NPC1 697/4885GLA 2014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback